Skip to content
Research Article Open access CC BY 3.0

Rock Inhibitors: Future of Anti-glaucoma Medication

Vishal Vohra, Harshika Chawla, Malvika Gupta

Ophthalmology Research: An International Journal · pp. 361–367 · Published 8 Jul 2014

10.9734/OR/2014/10573

Abstract

Glaucoma constitutes the major burden of irreversible blindness worldwide as of today. All the modalities of treatment are focussed on lowering intraocular pressure (IOP), from medical to surgical. With the advent of new drugs, drug compliance has increased among the patients but still is the most worrisome problem for doctors. Current research is focussed to treat glaucoma by means other than just lowering IOP. Among the various molecules under trial, one group is Rho kinaseinhibitors (ROCK INHIBITORS). They modulate cellular motility of the trabecular meshwork, schlemm’s canal, and ciliary muscle, thereby enhancing aqueous drainage. Being still under trials, hopes are on that these could revolutionise glaucoma therapy.  

Rho kinase inhibitors ROCK inhibitors glaucoma trabecular meshwork remodeling

Cited by 1

Rho-kinase (ROCK) Inhibitors - A Neuroprotective Therapeutic Paradigm with a Focus on Ocular Utility

Vasudha Abbhi, Poonam Piplani · Current Medicinal Chemistry · 2020

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

1

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.